Which of the following is NOT a known side effect of Topical Prostaglandins?

Topical prostaglandins, commonly used in the treatment of glaucoma, have a range of known side effects, and understanding these is important for both patient counseling and management.

Iris heterochromia refers to a change in the color of the iris, which is a well-documented side effect of topical prostaglandins. This occurs because these agents can increase the amount of melanin in the melanocytes of the iris, leading to darkening of the color in individuals with lighter-colored eyes.

Similarly, increased pigmentation on the skin is also associated with the use of topical prostaglandins. Patients may notice darkening of the eyelid skin or periorbital tissues, which has been observed particularly in individuals using these medications long-term.

Additionally, the growth of eyelashes is a notable effect of prostaglandins, leading to the marketing of some of these substances for cosmetic use in enhancing eyelash length and density (e.g., bimatoprost).

In contrast, aplastic anemia is not a recognized side effect of topical prostaglandins. Aplastic anemia is a serious condition in which the bone marrow fails to produce sufficient blood cells. This condition is unrelated to the pharmacological effects of topical prostaglandins, which